Microbiome Insights' co-founders participate in Personalized Medicine Initiative webinar

MARCH 29, 2017 – Two of Microbiome Insights' co-founders, CEO Malcolm Kendall and Dr. Bill Mohn, were key speakers this week in a webinar organized by British Columbia's Personalized Medicine Initiative (PMI). The webinar, open to participants across North America, focused on how microbiome research will contribute to personalized medicine as our knowledge advances.

“Microbiome Insights is proud to be part of a dynamic community working toward a more personalized approach to medical care, as the microbiome shows great promise for helping this field move forward,” says Kendall. The company, founded under the umbrella of the Personalized Medicine Initiative, enables both academic and industrial clients to seamlessly complete their microbiome research.

The PMI is a broad organization of personalized medicine stakeholders and resources in British Columbia; its mission is to introduce technologies enabling personalized (molecularly-based) medicine to the front lines of healthcare, facilitating a more efficient medical system. The PMI also serves as an educational and information resource for residents and medical practitioners. The organization is led by a Board of Directors that includes Pieter Cullis (Chair), David Huntsman, Bruce McManus, Martin Dawes and James Russell, with input from an Advisory Committee that represents a cross-section of interests relating to healthcare, science, technology, ethics, and health policy.

 

About Microbiome Insights

Microbiome Insights, Inc. is a global leader providing end-to-end microbiome sequencing and comprehensive bioinformatic analysis. The company is headquartered in Vancouver, Canada where samples from around the world are processed in its College of American Pathologist (CAP) accredited laboratory. Working with clients from pharma, biotech, nutrition, cosmetic and agriculture companies as well as with world leading academic and government research institutions, Microbiome Insights has supported over 925 microbiome studies from basic research to commercial R&D and clinical trials. The company's team of expert bioinformaticians and data scientists deliver industry leading insights including biomarker discovery, machine-learning based modelling and customized bioinformatics analysis.